Executive appointments at Verona Pharma

3 January 2019

UK clinical-stage biopharma firm Verona Pharma (AIM: VRP) today announced the expansion of its global clinical development team with the appointment of Kathleen Rickard as chief medical officer, and Tara Rheault as vice president of R&D operations and global project management.

Drs Rickard and Rheault will be based in the company’s US offices from where they will leverage their expertise to help drive global R&D activities. Dr Rickard is expected to start in her role on February 1, 2019 and Dr Rheault started in her role on January 1, 2019.

In her new role, Dr Rickard brings 25 years of experience in clinical research in respiratory medicine, industry, and management to lead the clinical development of RPL554, Verona Pharma’s first-in-class product candidate in development for the maintenance treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and potentially asthma.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK